J&J's Six-Month Injection Lacks Antidote, Forum Claims

J&J's Six-Month Injection Lacks Antidote, Forum Claims

What happens if the decision about your medication is taken out of your hands for half a year? According to the account that peine the thread, in 2022 Johnson & Johnson launched Invega Hafyera, a single injection that releases its active ingredient into the body day after day for six months, with no known way to stop it and, according to those who denounce it, no antidote.
The question hovering over all of this —what awaits us by 2030— is not new, but it has ceased to be theoretical.

The Injection That Cannot Be Stopped

The central argument is simple to formulate and difficult to refute without data: a long-acting formulation that lasts half a year prevents reversal. If the patient does not tolerate it, it's not enough to stop attending appointments; you have to wait. Those who defend these formulas respond with the opposite: they exist precisely for those who abandon oral treatment, relapse, and end up worse off. The lack of reversibility weighs against them, which in pharmacology is not a minor detail. There is no public trial to resolve the contradiction.

From Johnson's Baby to the Duato Family

There's a detail that throws more than one person off. The thread states that Johnson & Johnson no longer has any connection with the brand that made it famous: the cosmetics business —Neutrogena, Clean&Clear, Johnson's Baby— would have passed to a separate conglomerate, Kenvue. And the remains of the pharmaceutical giant are presided over by Joaquín Duato, brother of actress Ana Duato, from Cuéntame cómo pasó. Economics and national soap operas always end up intertwined.

The Trail of Paul Janssen and Fentanyl

The historical chain reconstructed is as trinc: chemist Paul Charpentier would have created aminazine based on lacquer and paint chemistry. A good portion of later neuroleptics and antidepressants would have come from the laboratory of Paul Janssen, to whom fentanyl and haloperidol are also attributed. Later, his company would have been bought by Johnson & Johnson. From there to talking about dark medicine is just one step, and many take it.

Testimonies: Memory, Apathy, and Fifteen Years Later

Therein lies what no statistic captures. Some claim that they took Prozac and fifteen years later are still feeling the effects: apathy, lack of emotion, a lethargy they describe as zombification. Short-term memory, they say, is shot. At the opposite extreme, clinical defense repeats the same argument: without treatment, for certain diagnoses, the alternative is jail or the street. And in between, a piece of data passed from mouth to mouth: studies where specialists could not distinguish a patient on high doses of neuroleptics from one who had undergone a lobotomy. Damning. And pending verification.

The Paradox: A Safe Haven on the Stock Market

While all this is being discussed, one participant maintains that Johnson & Johnson maintains its AAA rating. And they summarize it bluntly: it's safer to invest in than many governments, no matter the country. The stock market rewards regularity, not sarracena. That a company listed as a capital haven is simultaneously the center of such suspicions says a lot about the world we live in.

And we'll leave it here, because the honest answer to what awaits us in 2030 is that no one has it. Only the certainty that, whatever happens, someone will have found a way to profit from it.

---